Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Baxter
Express Scripts
McKesson
Colorcon

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

Lesinurad - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for lesinurad and what is the scope of freedom to operate?

Lesinurad is the generic ingredient in one branded drug marketed by Ironwood Pharms Inc and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lesinurad has one hundred and ninety-three patent family members in forty countries.

One supplier is listed for this compound.

Summary for lesinurad
International Patents:193
US Patents:9
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 61
Clinical Trials: 19
Patent Applications: 95
DailyMed Link:lesinurad at DailyMed
Recent Clinical Trials for lesinurad

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Medpace, Inc.Phase 4
Ironwood Pharmaceuticals, Inc.Phase 4
Ardea Biosciences, Inc.Phase 1

See all lesinurad clinical trials

Synonyms for lesinurad
(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid
{[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid
09ERP08I3W
2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid
2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid
2-(5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid
2-[[5-Bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-acetic acid
2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid
2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]acetic acid
2-{[5-broMo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid
3777AH
878672-00-5
AC-29310
Acetic acid, 2-((5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl)thio)-
Acetic acid,[[5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-
ACN-050764
AK323774
AKOS027327368
BCP06435
BDBM37953
C17H14BrN3O2S
CHEBI:90929
CHEMBL2105720
CS-1389
D09921
DB11560
EX-A1289
FGQFOYHRJSUHMR-UHFFFAOYSA-N
GTPL7673
HY-15258
KB-78121
KS-00000LAE
Lesinurad (RDEA-594)
Lesinurad (RDEA594 pound(c)
Lesinurad (RDEA594)
Lesinurad (USAN/INN)
Lesinurad [USAN:INN]
Lesinurad, >=98% (HPLC)
MolPort-039-138-666
RDEA 594
RDEA-594
RDEA594
s4640
SB16705
SC-94287
SCHEMBL842962
UNII-09ERP08I3W
US10093631, Compound Lesinurad
W-5949
ZINC84757007
Zurampic
Zurampic (TN)

US Patents and Regulatory Information for lesinurad

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 DISCN Yes No   Start Trial   Start Trial   Start Trial
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 DISCN Yes No   Start Trial   Start Trial   Start Trial
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for lesinurad

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2217577 2016016 Norway   Start Trial PRODUCT NAME: LESINURAD, ELLER ET; REG. NO/DATE: EU/1/15/1080 20160303
2135608 93169 Luxembourg   Start Trial PRODUCT NAME: LESINURAD , OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION DATE: 20160222
2217577 122019000008 Germany   Start Trial PRODUCT NAME: DUZALLO - ALLOPURINOL / LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/18/1300 20180823
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Moodys
Johnson and Johnson
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.